证券代码：688513 证券简称：苑东生物 公告编号：2025-051 二、风险提示 （一）本次询价转让受让方及受让股数仅为初步结果，尚存在拟转让股份被 司法冻结、扣划等风险。询价转让的最终结果以中国证券登记结算有限责任公司 上海分公司最终办理结果为准。 成都苑东生物制药股份有限公司 股东询价转让定价情况提示性公告 成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、 成都菊苑投资合伙企业（有限合伙）（以下合称"出让方"）保证向成都苑东生物 制药股份有限公司（以下简称"苑东生物"、"公司"）提供的信息内容不存在任 何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承 担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据 2025 年 7 月 23 日询价申购情况，初步确定的本次询价转让价格为 42.06 元/股。 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为 42.06 元/股。 （二）参与本次询价转让报价的机构投资者家数为 12 家，涵盖了基金管理 公司、保险公司、证券公司、私募基金管理人等专业 ...

苑东生物公告，根据2025年7月23日询价申购情况，初步确定的本次询价转让价格为42.06元/股。参与 本次询价转让报价的机构投资者家数为12家，参与机构包括基金管理公司、保险公司、证券公司、私募 基金管理人等。有效认购股份数量为540万股，对应转让底价的有效认购倍数为1.6倍。本次询价转让拟 转让股份已获全额认购，初步确定受让方为10家机构投资者，拟受让股份总数为336.95万股。 ...

Group 1 - Hualing Cable recently won multiple contracts totaling approximately 557 million yuan, accounting for 13.40% of its audited revenue for 2024 [1] - The projects include contracts from Southern Power Grid, China Institute of Atomic Energy, Zijin Mining, Tianjin Rail Transit, and China Nonferrous Metal International Mining [1] Group 2 - Weisi Medical's shareholder plans to reduce its stake by up to 3%, totaling no more than 2.8731 million shares, due to personal funding needs [2] - Han Yi Co. intends to invest 102 million yuan to acquire a 39% stake in Shanghai Pidong Cultural Media, aiming to expand its IP derivative business [2] Group 3 - Zhongsheng High-Tech's controlling shareholder will change to Fuzhou Qianjing after signing a share transfer agreement, with stock resuming trading [3] - Tianli Lithium Energy plans to invest 30% in a joint venture for advanced energy research, contributing 30 million yuan [5] Group 4 - Zhenbang Intelligent plans to invest up to 11 million USD to establish a production base in Indonesia [8] - Shenhuo Co. aims to set up a 1.512 billion yuan industry fund focusing on strategic emerging industries [9] Group 5 - Shenhuo Co. intends to acquire a 14.69% stake in Shenhuo New Materials for 298 million yuan through public bidding [11] - Kema Technology plans to acquire a 73% stake in Suzhou Kaixin Semiconductor for 102 million yuan to enhance its capabilities in silicon carbide materials [13] Group 6 - China Power Construction's subsidiary won two major engineering projects with total contract values of approximately 57.52 billion yuan and 54.39 billion yuan [14] - Huaxin Environmental plans to reduce its stake by up to 1.58% due to personal funding needs [15] Group 7 - Yuandong Bio's shareholders plan to collectively reduce their stake by up to 1.91% for personal funding needs [17] - Xiangming Intelligent's controlling shareholder plans to reduce its stake by up to 3% due to personal funding needs [18] Group 8 - Sand Technology's actual controller's associates plan to reduce their stake by up to 2% for personal funding needs [19] - Beifang Changlong decided to terminate the acquisition of 51% of Henan Zhongzheng due to changes in market conditions [20] Group 9 - ST Huicheng plans to publicly transfer 30% of its subsidiary Peak Intelligent for a starting price of 5.1 million yuan [22] - Yunji Group's major shareholder plans to reduce its stake by up to 3% for personal funding needs [23] Group 10 - Shunbo Alloy plans to raise up to 600 million yuan through a private placement to enhance its main business [24] - Berry Gene's major shareholder will face judicial enforcement on 1% of its shares due to a pledge default [25] Group 11 - Guanglian Aviation's controlling shareholder is under investigation, but the company's operations remain normal [26]

Core Viewpoint - The company, Yuandong Biopharmaceutical Co., Ltd., is planning a non-public transfer of shares amounting to 3,369,550 shares, which represents 1.91% of its total share capital, to institutional investors through a pricing inquiry process [2][5]. Group 1: Share Transfer Details - The shareholders participating in the share transfer are Chengdu Nanyuan Investment Partnership, Chengdu Zhuyuan Investment Partnership, and Chengdu Juyuan Investment Partnership [2]. - The controlling shareholder and actual controller of the company will not participate in this share transfer, ensuring that their shares remain intact [2][3]. - The transfer is being organized by CITIC Securities, and the shares have been released from any restrictions, confirming clear ownership [3][4]. Group 2: Pricing and Transfer Conditions - The total number of shares to be transferred is 3,369,550, with the transfer price being set at a minimum of 70% of the average trading price over the 20 trading days prior to July 22, 2025 [5][6]. - The transfer process will prioritize price, quantity, and time of submission for determining the allocation of shares among interested institutional investors [7]. Group 3: Investor Eligibility - Eligible investors for this share transfer include institutional investors with appropriate pricing capabilities and risk tolerance, such as securities companies, fund management companies, and qualified foreign institutional investors [8]. Group 4: Company Status and Risks - The company does not face any operational risks or potential changes in control due to this share transfer, and there are no other undisclosed significant matters [9].

证券代码：688513 证券简称：苑东生物 公告编号：2025-050 成都苑东生物制药股份有限公司 股东询价转让计划书 成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、 成都菊苑投资合伙企业（有限合伙）（以下合称"出让方"）保证向成都苑东生物 制药股份有限公司（以下简称"公司"或"苑东生物"）提供的信息内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担 法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ? 拟参与苑东生物首发前股东询价转让（以下简称"本次询价转让"）股东 为成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、 成都菊苑投资合伙企业（有限合伙）； ? 公司控股股东、实际控制人直接或间接持有的股份不参与本次询价转让； ? 本次询价转让为非公开转让，不会通过集中竞价交易方式进行。受让方 通过询价转让受让的股份，在受让后 6 个月内不得转让； ? 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出 ...

中信证券股份有限公司 关于成都苑东生物制药股份有限公司股东 向特定机构投资者询价转让股份 相关资格的核查意见 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 1 中信证券股份有限公司（以下简称"中信证券"）受成都苑东生物制药股份 有限公司（以下简称"苑东生物"）股东成都楠苑投资合伙企业（有限合伙）、 成都竹苑投资合伙企业（有限合伙）、成都菊苑投资合伙企业（有限合伙）（以 下简称"出让方"）委托，组织实施本次苑东生物首发前股东向特定机构投资者 询价转让（以下简称"本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》《科创 板上市公司持续监管办法（试行）》《上海证券交易所科创板股票上市规则（2025 年 4 月修订）》《上海证券交易所科创板上市公司自律监管指引第 4 号——询价 转让和配售（2025 年 3 月修订）》（以下简称"《询价转让和配售指引》"）等 相关规定，中信证券对参与本次询价转让股东的相关资格进行核查，并出具本核 查意见。 一、本次询价转让的委托 中信证券收到出让方关于本次询价转让的委托，委托中信证券组织实施本次 询价转让。 二、关于参与本次询价转让股东相关 ...

证券代码：688513 证券简称：苑东生物 公告编号：2025-050 成都苑东生物制药股份有限公司 股东询价转让计划书 成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、 成都菊苑投资合伙企业（有限合伙）（以下合称"出让方"）保证向成都苑东生物 制药股份有限公司（以下简称"公司"或"苑东生物"）提供的信息内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担 法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 拟参与苑东生物首发前股东询价转让（以下简称"本次询价转让"）股东 为成都楠苑投资合伙企业（有限合伙）、成都竹苑投资合伙企业（有限合伙）、 成都菊苑投资合伙企业（有限合伙）； 公司控股股东、实际控制人直接或间接持有的股份不参与本次询价转让； 本次询价转让为非公开转让，不会通过集中竞价交易方式进行。受让方 通过询价转让受让的股份，在受让后 6 个月内不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资 者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中信证券 ...

苑东生物公告，成都楠苑投资合伙企业(有限合伙)、成都竹苑投资合伙企业(有限合伙)、成都菊苑投资 合伙企业(有限合伙)计划参与公司首发前股东询价转让，拟转让股份总数为336.95万股，占公司总股本 的1.91%。本次询价转让为非公开转让，受让方通过询价转让受让的股份在受让后6个月内不得转让。 受让方为具备相应定价能力和风险承受能力的机构投资者。转让原因为自身资金需求，价格下限不低于 发送认购邀请书之日(2025年7月22日)前20个交易日股票交易均价的70%。 ...

688513 2025 Chengdu Easton Biopharmaceuticals Co.,Ltd. 8 610219 成都苑东生物制药股份有限公司 2025 年第一次临时股东大会会议资料 成都苑东生物制药股份有限公司 2025 年第一次临时股东大会会议资料目录 | 2025 年第一次临时股东大会会议资料目录. | | --- | | 2025 年第一次临时股东大会会议须知 | | 2025 年第一次临时股东大会会议议程 | | 2025 年第一次临时股东大会会议议案 | | 议案 1:《关于免去彭龙先生独立董事职务的议案》 | | 议案 2: 《关于补选公司第四届董事会独立董事的议案》 | 2 / 8 2025 2025 " " " " 2025 3 " " " " " " / 5 3 / 8 2025 / " " " " " " https://vote.sseinfo.com/i/yjt_help.pdf 4 / 8 2025 2025 1 2025 8 1 14 00 2 8 3 4 2025 8 1 2025 8 1 2025 8 1 9:15-9:25 9:30-11:30 13:00-1 ...

Group 1 - Senyuan Electric signed a strategic cooperation agreement with Xuchang Digital Supply Chain Management Co., aiming for annual business cooperation not exceeding 500 million yuan over 36 months [1] - CICC's subsidiary, CICC Wealth, reported a net profit of 987 million yuan for the first half of the year, with total assets of 193.37 billion yuan [2] - Shuangjie Electric expects a net profit of 100 million to 120 million yuan for the first half of the year, representing a year-on-year increase of 16.03% to 39.23% [3][4] - Shentong Technology reported a net profit of 64.28 million yuan for the first half of the year, a year-on-year increase of 111.09% [5] - Suqian Nongfa's net profit for the first half of the year decreased by 27.72% to 213 million yuan [6] Group 2 - Fuan Pharmaceutical expects a net profit decline of 39.95% to 53.81% for the first half of the year, estimating between 100 million to 130 million yuan [8] - Xingwang Yuda anticipates a net loss of 11 million to 21 million yuan for the first half of the year [9] - Pulaike received a new veterinary drug registration certificate for a vaccine aimed at preventing chicken diseases [10] - Yuandong Biological's ephedrine injection received a drug registration certificate for treating low blood pressure during anesthesia [11] - Suqian Liansheng's subsidiary obtained two invention patent certificates [12] Group 3 - Oke Technology signed a 176 million yuan equipment order with Jiangxi Tianhong New Materials [13] - Publishing Media announced the resignation of its chief accountant due to work changes [15] - Zhongxin Co. plans to use 40 million yuan of idle funds for cash management [16] - Huiyun Titanium plans to use up to 58 million yuan of idle convertible bond funds for cash management [18] - Haineng Technology intends to apply for a credit facility of up to 200 million yuan from a bank [20] Group 4 - Jiabiou expects a net profit increase of 57.61% for the first half of the year, estimating around 107 million yuan [21] - Nanjing Gaoke reported a 1185% year-on-year increase in contract sales area for the second quarter [22] - Shuguang Co. received approval for a specific stock issuance application [23] - Huadong Pharmaceutical's subsidiary received approval for a clinical trial of a new drug targeting advanced solid tumors [23] - Quicheng Co. plans to invest 900 million yuan in two new projects [25] Group 5 - Shenlian Biological's vaccine for avian adenovirus received a new veterinary drug registration certificate [26] - Rike Chemical signed a strategic cooperation framework agreement with Dongming Petrochemical [28] - Jincheng Pharmaceutical's subsidiary received a renewed tobacco production license [29] - Magmi Te's stock issuance application was accepted by the Shenzhen Stock Exchange [29] - Zhongyin Securities received approval to issue bonds totaling up to 14 billion yuan [29] Group 6 - Hewei Electric's executives plan to reduce their holdings by a total of 2.24% of the company's shares [44] - Guo Wang Xintong reported a net profit of 266 million yuan for the first half of the year, a decrease of 10.82% [45] - Guo Wang Xintong's subsidiary won a 966 million yuan tender from the State Grid [46] - Jicheng Electronics won contracts worth approximately 83.79 million yuan from the State Grid [48] - Helen Piano is planning a change of control, leading to a temporary stock suspension [48]